People with multiple sclerosis (MS) have a higher risk of dying by suicide than the general population, according to a meta-analysis of published studies. Nearly one-quarter of participants in the studies had thoughts about suicide (suicidal ideation). Across the studies, 0.5% of participants died by suicide, which represented 2.1% of all deaths observed in people…
Category: Multiple Sclerosis Research
Fenebrutinib in PPMS
Tweet Roche announced in early Oct that their BTKi (Bruton’s Tyrosine Kinase inhibitor) was non-inferior to ocrelizumab (anti-B-cell) in PPMS. In a pivotal PPMS study (FENtrepid), fenebrutinib slowed disability progression at least as effectively as OCREVUS, the only approved therapy in PPMS [Ad hoc announcement pursuant to Art. 53 LR] This was measured by a…
Fall at the Mall
A shopping trip goes awry I’m pleased to report that I’ve still got it! Even as I approach my middle ages, I still can pull it off. Just a few weeks ago, I was picked up by not one, but two younger guys! Here’s how it went down. I had a doctor’s appointment in the…
New MS experimental therapy misses main goals in clinical trial
A Phase 2 clinical trial testing PIPE-307, an experimental therapy designed to support myelin repair in people with multiple sclerosis (MS), has failed to meet its primary or secondary efficacy goals. The U.S.-based VISTA trial (NCT06083753) enrolled more than 180 adults with relapsing-remitting MS (RRMS). Participants received one of two PIPE-307 doses or a placebo…
Sweet Dreams
Proper sleep is a quintessential part of functioning optimally. The average adult needs at least 7-8 hours of proper sleep. A loss of sleep can interfere with an individual’s ability to function at their full capacity, as it can lead … Continue reading → Source: blog.mymsaa.org
Alternative Dimethyl fumarate
Tweet Dimethyl fumarate has come out of patent and so diroxynel fumarate was developed, They both break down into monomethyl fumarate the active compound that inhibits MS. In USA monomethyl fumarate is approved for MS. Twgomil fumarate is “a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ already authorised in the…
Battle of the Block busters
Tweet The drug class being used increasingly are the anti-CD20 depleting drugs. There are more and more of them. So which do you choose? They all target CD2O and they are all based on human IgG1, but are they the same? The battle for the sales team is how they position thier drugs to get…
Guest Voice: Who knew MS and bipolar disorder were connected?
I am a 63-year-old psychologist, clinician, professor, and poster child for multiple sclerosis (MS). After more than 30 years with the disease, I’m still mobile, sometimes with a cane. My speech isn’t impaired, though my volume is, and my memory is taking a nosedive. I have no working taste buds, no proprioception, and I’m slow…
Nourishing November with Fall Traditions
By: Dr. Eva Jackson As the crisp air settles in and leaves turn golden, the fall season welcomes a tapestry of festivals, holidays, and cherished family gatherings. The sights of autumn begin with vibrant wreaths and pumpkins adorning front porches, … Continue reading → Source: blog.mymsaa.org
New Tysabri biosimilar Tyruko now on market for relapsing MS
Tyruko (natalizumab-sztn) is now commercially available in the U.S. as the first and only approved biosimilar to Tysabri for adults with relapsing forms of multiple sclerosis (MS). The therapy received approval from the U.S. Food and Drug Administration (FDA) in 2023 for all indications covered by the brand-name medicine, including clinically isolated syndrome, relapsing-remitting MS (RRMS),…